BlackRock Inc. purchased a new position in shares of Zynex Inc. (OTCMKTS:ZYXI) during the 2nd quarter, HoldingsChannel reports. The firm purchased 773,782 shares of the company’s stock, valued at approximately $6,957,000.
Several other institutional investors and hedge funds have also made changes to their positions in ZYXI. Northern Trust Corp acquired a new position in shares of Zynex during the 2nd quarter worth $627,000. Acadian Asset Management LLC increased its stake in shares of Zynex by 127.6% during the 2nd quarter. Acadian Asset Management LLC now owns 108,737 shares of the company’s stock worth $978,000 after purchasing an additional 60,960 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in shares of Zynex during the 2nd quarter worth $304,000. Charles Schwab Investment Management Inc. acquired a new position in shares of Zynex during the 2nd quarter worth $292,000. Finally, Wells Fargo & Company MN acquired a new position in shares of Zynex during the 2nd quarter worth $156,000. Institutional investors own 0.05% of the company’s stock.
In related news, CEO Thomas Sandgaard sold 104,450 shares of the firm’s stock in a transaction on Monday, October 7th. The shares were sold at an average price of $12.38, for a total value of $1,293,091.00. Insiders sold a total of 304,450 shares of company stock worth $3,470,270 over the last quarter.
Zynex (OTCMKTS:ZYXI) last announced its quarterly earnings results on Wednesday, July 31st. The company reported $0.06 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.06. Zynex had a net margin of 33.33% and a return on equity of 152.81%. The company had revenue of $10.30 million for the quarter, compared to analyst estimates of $9.84 million. Research analysts anticipate that Zynex Inc. will post 0.28 EPS for the current year.
ZYXI has been the topic of several analyst reports. Zacks Investment Research upgraded shares of Zynex from a “sell” rating to a “hold” rating in a research note on Thursday, June 27th. HC Wainwright initiated coverage on shares of Zynex in a research note on Monday, September 23rd. They set a “buy” rating and a $12.00 price target on the stock. Finally, B. Riley increased their price target on shares of Zynex from $10.75 to $12.00 and gave the stock a “buy” rating in a research note on Tuesday.
Zynex, Inc, a medical technology company, designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. Its products include NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; and InWave, an electrical stimulation product for the treatment of female urinary incontinence.
Read More: Dollar Cost Averaging
Want to see what other hedge funds are holding ZYXI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zynex Inc. (OTCMKTS:ZYXI).
Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with MarketBeat.com's FREE daily email newsletter.